PI3K/Akt/mTOR

Acadesine is a selective activator of AMPK in both hepatocytes and adipocytes.

A-769662 is a new activator of AMP-activated protein kinase (AMPK).

Metformin is an AMP-activated protein kinase (AMPK) activator that improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose.

MK8722 is a potent and systemic pan-AMPK activator.

PS 48 is an allosteric phosphoinositide-dependent protein kinase-1 (PDK1) activator (Kd = 10.3 μM).

SC79 is an AKT activator. SC79 binds to the plecktrin homology (PH) domain of Akt that mimics the binding of PtdIns(3,4,5)P3 to induce a conformational change in Akt that enhances phosphorylation and activation.

ETC-1002 is a novel, first-in-class, orally available, once-daily LDL-C lowering small molecule; activator of hepatic AMP-activated protein kinase (AMPK); also has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).

EX229 (compound 991) is a potent AMPK activator that is 5-10-fold more potent than A769662 in activating AMPK.

PF-06409577 is orally bioavailable AMPK activator with EC50 of 7 nM for α1β1γ1 in the TR-FRET assay and it shows no detectable inhibition of hERG in a patch-clamp assay (100 μM) and was not an inhibitor (IC50 > 100 μM) of the microsomal activities of major human cytochrome P450 isoforms.

7-Methoxyisoflavone is an isoflavone derivative and also an activator of adenosine monophosphate-activated protein kinase (AMPK).

IM156 (HL156A), a metformin derivative, is a potent activator of AMPK that increases AMPK phosphorylation.

3BDO is a new mTOR activator which can also inhibit autophagy.